Approximately 60% of patients with CPVT carry RYR2 mutations, and the main pathogenic mechanism of gain-of-function mutations is increased spontaneous RyR2 opening and pathological calcium release during diastole (17, 65, 115). The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.